Lung Cancer News

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.

Randomized Trial of Stepped vs Early Integrated Palliative Care for Lung Cancer

Randomized Trial of Stepped vs Early Integrated Palliative Care for Lung Cancer

Researchers are evaluating whether early integrated palliative care yields superior quality of life outcomes to stepped palliative care.

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

The safety profile of each agent was consistent with those previously reported.

NSCLC: Stratifying Patients With Complex EGFR Mutations

NSCLC: Stratifying Patients With Complex EGFR Mutations

Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.

Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer

Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer

AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.

Phase 2 Study of Tremelimumab Plus Durvalumab Alone or With Radiation for SCLC

Phase 2 Study of Tremelimumab Plus Durvalumab Alone or With Radiation for SCLC

Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.

Phase 2 Study of Pembrolizumab vs Topotecan for Small-Cell Lung Cancer

Phase 2 Study of Pembrolizumab vs Topotecan for Small-Cell Lung Cancer

Researchers are comparing the effectiveness of pembrolizumab with that of topotecan among patients with SCLC.

Cigar and Pipe Use Significantly Increase Mortality Risk

Cigar and Pipe Use Significantly Increase Mortality Risk

Non-cigarette tobacco use has increased by over 100% in the last 2 decades.

FDA Approves Durvalumab for Prevention of NSCLC Progression

FDA Approves Durvalumab for Prevention of NSCLC Progression

The FDA based its approval on positive findings from the phase 3 PACIFIC study.

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.

Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition

Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition

Researchers are evaluating whether adding a dendritic cell-based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC.

BMI, Age, and Treatment Response May Predict for Survival in Patients With Lung Cancer

BMI, Age, and Treatment Response May Predict for Survival in Patients With Lung Cancer

Researchers retrospectively analyzed the outcomes of 78 patients with stage IV lung SCC who were treated with gemcitabine plus cisplatin as first-line therapy.

Elderly Patients With NSCLC Are Often Undertreated

Elderly Patients With NSCLC Are Often Undertreated

Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.

FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC

FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC

Data from FLAURA may position osimertinib as the first-line standard of care for patients with EGFR-mutant NSCLC.

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs